<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485978</url>
  </required_header>
  <id_info>
    <org_study_id>EARLY_PRO-TECT_ALPORT</org_study_id>
    <nct_id>NCT01485978</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome</brief_title>
  <official_title>Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multi-centre, randomised, placebo-controlled, patient and
      investigator-blind study in paediatric patients with early stages of Alport syndrome to
      assess the safety and efficacy of the ACEi ramipril in slowing disease progression.

      Alport syndrome stages that describe the extent of renal damage and loss of function are
      defined as:

        -  0 Microhaematuria without microalbuminuria (usually at birth)

        -  I Microalbuminuria (30-300 mg albumin/gCrea)

        -  II Proteinuria &gt;300 mg albumin/gCrea

        -  III &gt; 25% decline of normal renal function (creatinine clearance)

        -  IV End stage renal failure (ESRF)

      Eligible patients with Alport stages 0 and I will be randomly assigned at a 2:1 ratio to
      receive once daily ramipril or placebo. In addition, Alport stage II patients may be treated
      open Label. Eligible patients who, or whose parents/legal guardian refuse randomisation after
      eligibility is confirmed, and patients who have been treated with ramipril prior to the
      study, may be treated open-label with ramipril as per protocol. The total number of patients
      will not exceed 120, with the number of randomised patients not exceeding 60, and the number
      of patients treated open label from Day 1 of the study aimed to be approximately 60.

      Randomised patients whose disease progresses to the next disease level during the 3 year
      treatment period will be unblinded, and open label ramipril treatment will be initiated and
      continued, respectively, depending on prior treatment randomisation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next disease level</measure>
    <time_frame>within 3 years</time_frame>
    <description>Time to progression of Alport Syndrome to the next disease level within 3 years under ramipril treatment compared to placebo, for all randomised patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Drug Events before progression</measure>
    <time_frame>within 3 years</time_frame>
    <description>Incidence of adverse drug events (ADEs, e.g., angioedema, acute renal failure, hyperkalaemia) under ramipril treatment before disease progression compared to placebo before disease progression, for all randomised patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuminuria after three years</measure>
    <time_frame>after 3 years</time_frame>
    <description>Albuminuria after 3 years corrected for baseline albuminuria for patients randomised to receive ramipril compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Events over three years</measure>
    <time_frame>after 3 years</time_frame>
    <description>Incidence of ADEs (e.g., angioedema, acute renal failure, hyperkalaemia) during 3 years of treatment for patients randomised to receive ramipril compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Ramipril blinded</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo to ramipril</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>open label ramipril</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label treatment with ramipril as per protocol, if randomization is refused.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.</description>
    <arm_group_label>Ramipril blinded</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to ramipril</intervention_name>
    <description>Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.</description>
    <arm_group_label>placebo to ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.</description>
    <arm_group_label>open label ramipril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected
             relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous
             autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria,
             positive family history regarding kidney diseases, ocular changes, labyrinthine
             hearing loss)

          -  Alport syndrome levels 0, I or II at screening (microhaematuria without
             microalbuminuria or microalbuminuria [30-300 mg albumin/gCrea]) or proteinuria &gt;300 mg
             albumin/gCrea with GFR&gt;80ml/min). Patients with Alport stage II are not subject to
             randomization but are treated opel label.

          -  Aged between â‰¥24 months and &lt;18 years at screening

          -  Assent from patient and informed consent from parents/legal guardian

        Exclusion Criteria:

          -  Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier

          -  Alport syndrome levels III, or IV (albuminuria &gt;300 mg/g Crea, creatinine clearance
             &lt;60 mL/min, or end stage renal failure [ESRF])

          -  Known allergies or intolerances to ramipril or related compounds

          -  Known contraindication for ACEi-therapy

          -  Additional chronic renal, pulmonary or cardiac diseases

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Gross, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Goettingen, Department Nephrology and Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.alport.de</url>
    <description>Related Information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alport Syndrome</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>renal fibrosis</keyword>
  <keyword>nephroprotection</keyword>
  <keyword>pediatric study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Nephritis, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

